NEW YORK (GenomeWeb) – Myriad Genetics sued Pathway Genomics on June 13 for infringement of its patent claims underlying BRCA1 and BRCA2 genetic testing.

San Diego-based Pathway issued a statement today stating that it will "vigorously defend" itself against that suit. The legal challenge was spurred by Pathway's launch earlier this month of a next-generation sequencing test for gauging alterations in BRCA1 and BRCA2 genes, called BRCATrue.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: mitochondrial and nuclear gene fusions in cancer, role of genomic imprinting in tissue-specific gene expression, and more.

Maria Freire from the Foundation for the NIH calls for "politically popular pledges of support" for the NIH to turn into support for increased funding for the agency.

A Thomson Reuters analysis indicates that the life sciences, rather than the tech sector, are increasingly driving global innovation.

The White House says ethical discussions about genome editing of the human germline are needed.